WASHINGTON, DC—The ACURATE investigational device exemption (IDE) trial has provided disappointing results, with the Acurate neo2 TAVI valve (Boston Scientific) falling short of noninferiority versus ...

Boston Scientific will eliminate jobs after discontinuing global sales of its Acurate aortic valve replacement systems that treat the heart failure-causing condition aortic stenosis, the medtech ...

PARIS, France—More than one in five Acurate neo2 transcatheter heart valves (Boston Scientific) implanted in patients as part of the ACURATE investigational device exemption (IDE) study were ...

ACURATE neo2 was developed after its predecessor ACURATE neo, a self-expanding valve for TAVR, did not achieve outcomes similar to those of SAPIEN and Evolut valves in randomized controlled trials.

Boston Scientific said on Wednesday it has discontinued sales of its heart device in the European Union and will not seek approval in the U.S. and other markets due to increased clinical and ...

Boston Scientific (BSX) Corporation announced the results of the primary endpoint of the ACURATE IDE clinical trial, which evaluated the ACURATE neo2 Aortic Valve System in the treatment of ...

BOSTON — Transcatheter aortic valve replacement with the self-expanding Acurate neo device was similar to the balloon-expandable Sapien 3 device in clinical outcomes at 3 years, according to new ...

Boston Scientific on Wednesday said it is ending worldwide sales of its Acurate neo2 and Prime aortic-valve systems, and that it is no longer pursuing regulatory approvals for Acurate in the U.S ...

The trial was the largest to date of Acurate neo2, enrolling 1,500 patients with severe aortic stenosis at all risk levels for open surgery. The valve delivered a composite rate of 16.16% versus ...